Klin Onkol 2002; 15(Suppl 2002): 44-47.
Summary: Malignant cells in multiple myeloma produce a monoclonal immunoglobulin which is tumor-specific and can be used for the induction of T lymphocytes. Idiotypic (Id) structures are expressed at the cell surface of malignant plasma cells and allow the recognition and targeting of these cells by Id-specific T lymphocytes. The induced humoral and cellular immune response controls the growth of the malignant cell clone. Vaccination using Id-protein has been attempted in patients with multiple myeloma and other B cell malignancies. The aim of this therapy is to induce specific immune response directed against the tumor cells. Id-protein may be used for cell-free vaccines where it is administered alone or after conjugation with a suitable adjuvans, and for cellular vaccines where it is loaded into dendritic cells. We review preclinical and clinical results of Id-specific vaccinations for multiple myeloma.
